Abstract 3435
Background
Adult primary malignant brain tumours are rare; however, they have a devastating impact and a poor prognosis (Ford et al., 2012). For the past seven years the National Cancer Patient Experience Survey (Quality Health, 2014) has reported the care of brain tumour patients as being less positive compared to other cancer sites, possibly due to unmet care needs. The Aims of this research were: - To explore registered medical nurses’ experiences of the care needs of adult patients with a primary brain tumour. - To identify possible gaps in knowledge and skills that limit the provision of optimal care.
Methods
The project adopted a qualitative methodological approach using semi-structured interviews to collect and analyse data to reflect the experiences of medical nurses’ in the aforementioned care context. Three participants volunteered, who met the inclusion/exclusion criteria. Participants were registered nurses who had worked on the oncology/haematology Triage Unit for 12 months or more so that they had meaningful reflection.
Results
Themes emerged from the collection and analysis of data. Three main themes emphasised that the experience was: challenging; involved holistic care and depended on nurses’ knowledge and experience. Published literature identified that brain tumour patients were different to other cancer patients because they require more nursing time to address their complex care needs. The findings highlighted that senior nurses were significantly more knowledgeable, holistic and aware of patient needs.
Conclusions
Junior nurses felt they had very limited experience, confidence or knowledge to care for adult patients with a primary brain tumour. They acknowledged that education and training was essential to allow staff involved in the care of adult patients with a primary brain tumour to feel confident enough to be able to assess and care for the complex needs of this group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Birmingham City University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract